Bristol-Myers Squibb Co (BMY)

Add to Watchlists
Create an Alert
54.75 +0.33  +0.61% NYSE Oct 23, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All BMY News

News

View All Events

Events

Date Type Description
01/24/2020 10:30 EST Misc Bristol-Myers Squibb Co Fourth Quarter Earnings Conference Call in 2019
01/24/2020 Earnings Bristol-Myers Squibb Co Fourth Quarter Earnings in 2019 Release
10/31/2019 08:30 EDT Misc Bristol-Myers Squibb Co Third Quarter Earnings Conference Call for 2019
10/31/2019 Earnings Bristol-Myers Squibb Co Third Quarter Earnings Results for 2019
10/03/2019 Dividends Amount: 0.41, Declared Date: Sep 11 2019, Pay Date: Nov 01 2019
07/25/2019 10:30 EDT Misc Bristol-Myers Squibb Co Second Quarter Earnings Conference Call in 2019
07/25/2019 Earnings Bristol-Myers Squibb Co Second Quarter Earnings in 2019 Release
07/03/2019 Dividends Amount: 0.41, Declared Date: Jun 13 2019, Pay Date: Aug 01 2019
05/29/2019 Misc Bristol-Myers Squibb Co Annual General Meeting in 2018
04/25/2019 10:30 EDT Misc Bristol-Myers Squibb Co First Quarter Earnings Conference Call in 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 23.86B
Total Expenses (TTM) 17.04B
Net Income (TTM) 6.203B

Balance Sheet View Statement

Total Assets (Quarterly) 55.16B
Total Liabilities (Quarterly) 39.01B
Shareholders Equity (Quarterly) 16.05B

Cash Flow Statement View Statement

Cash from Operations (TTM) 7.181B
Cash from Investing (TTM) 1.292B
Cash from Financing (TTM) 14.94B

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.bms.com
  • Investor Relations URL: N/A
  • HQ State/Province: New York
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Oct. 31, 2019
  • Last Earnings Release: Jul. 25, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Oct. 03, 2019
  • Description: Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 54.75
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
VGHCX Vanguard Health Care Inv 5.16%
FDSBX AIG Focused Dividend Strategy B 3.87%
SCHD Schwab US Dividend Equity ETF™ 2.90%
MOAT VanEck Vectors Morningstar Wide Moat ETF 2.66%
XLV Health Care Select Sector SPDR® ETF 2.54%
IYH iShares US Healthcare ETF 2.34%
DODGX Dodge & Cox Stock 2.24%
VHT Vanguard Health Care ETF 2.08%
OIEQX JPMorgan Equity Income R4 1.87%
VWELX Vanguard Wellington™ Inv 0.84%
FISRX Franklin Income R 0.78%
FVD First Trust Value Line® Dividend ETF 0.55%

Comparables

Edit
AMGN Amgen Inc
CELG Celgene Corp
GILD Gilead Sciences Inc
JNJ Johnson & Johnson
LLY Eli Lilly and Co

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.